Clovis Oncology logo
Clovis Oncology CLVS

Quarterly report 2022-Q3
added 11-09-2022

report update icon

Clovis Oncology Accounts Payables 2011-2026 | CLVS

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.
Main types of accounts payable
Type of liabilityExample
To suppliers and contractorsGoods received but not yet paid for
Taxes and feesVAT, income tax, etc., not paid on time
SalariesEmployee wages not paid
To budgetsInsurance contributions to funds not paid
To foundersFounders provided borrowed funds
To banksOverdue loan payments
OtherFines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance
  1. Liquidity and solvency
    Accounts payable are part of short-term liabilities, so they affect liquidity ratios
  2. Financial stability
    The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
  3. Capital turnover
    Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
  4. Risks and reputation
    Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Clovis Oncology

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
27.3 M 26.7 M 32.2 M 28.5 M 15.1 M 10.9 M 11.3 M 2.92 M 4.42 M 2.3 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
32.2 M 2.3 M 16.2 M

Quarterly Accounts Payables Clovis Oncology

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- 18.1 M 24.2 M 22.3 M 27.3 M 23.8 M 22.5 M 20.5 M 26.7 M 26.7 M 26.7 M 26.7 M 32.2 M 32.2 M 32.2 M 32.2 M 28.5 M 28.5 M 28.5 M 28.5 M 15.1 M 15.1 M 15.1 M 15.1 M 10.9 M 10.9 M 10.9 M 10.9 M 11.3 M 11.3 M 11.3 M 11.3 M 2.92 M 2.92 M 2.92 M 2.92 M 4.42 M 4.42 M 4.42 M 4.42 M 2.3 M 2.3 M 2.3 M 2.3 M 3.04 M 3.04 M 3.04 M 3.04 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
32.2 M 2.3 M 15.1 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer Accounts Payables Price % 24h Market Cap Country
AgeX Therapeutics AgeX Therapeutics
AGE
1.93 M - -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
570 M - - $ 866 M chinaChina
Exelixis Exelixis
EXEL
29.6 M $ 48.43 9.03 % $ 13.2 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
14.2 M $ 2.56 3.96 % $ 71.4 M usaUSA
Athira Pharma Athira Pharma
ATHA
4.59 M - - $ 269 M usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
28.1 M $ 76.96 2.27 % $ 12.3 B usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
4.02 M $ 86.14 4.15 % $ 7.28 B usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
3.38 M - - $ 231 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
5.23 M $ 229.83 -1.06 % $ 4.2 B usaUSA
INmune Bio INmune Bio
INMB
199 K $ 1.52 -1.3 % $ 37.6 M usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
3.68 M $ 41.84 4.26 % $ 3.6 B usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
9.61 M $ 107.42 1.52 % $ 5.39 B usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
16.2 M $ 22.32 -0.13 % $ 3.7 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
9.03 M $ 3.68 28.5 % $ 1.12 B usaUSA
Advaxis Advaxis
ADXS
6.08 M - -9.65 % $ 45.9 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
65.1 M $ 3.13 0.55 % $ 651 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
561 K $ 3.47 -8.44 % $ 5.71 M israelIsrael
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
677 K - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
2.91 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
611 K - 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
9.03 M - - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.91 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
724 K - -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
1.28 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
6.52 M - -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
1.76 M - - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
1.28 M - 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
12.5 M $ 23.86 1.88 % $ 3.04 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
1.03 M - 3.16 % $ 1.9 M usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
5.06 M $ 7.5 2.04 % $ 375 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
750 K - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
1.58 M - - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
4.29 M - - $ 2.17 B usaUSA